

ISOLAGEN INC  
Form 4  
June 13, 2007

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
CIALLELLA SUSAN STRANAHAN

(Last) (First) (Middle)  
107 STONEPINE DRIVE  
(Street)

KENNETT SQUARE, PA 19348

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
ISOLAGEN INC [ILE]

3. Date of Earliest Transaction  
(Month/Day/Year)  
06/12/2007

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_ 10% Owner  
\_\_\_ Officer (give title below) \_\_\_X\_\_\_ Other (specify below)  
Former Director and Officer

6. Individual or Joint/Group Filing(Check Applicable Line)  
\_X\_ Form filed by One Reporting Person  
\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)		
				(A) or (D)	Code	V	Amount	(D)	Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transaction Code	5. Number of	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. F...	9. Der...
---------------------------------	---------------------------	--------------------------------------	-----------------------------------	---------------------	--------------	--	---	---------	-----------

Edgar Filing: ISOLAGEN INC - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Year)	(Instr. 8)	Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)						
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	\$ 1.89						(1)	04/13/2016	Common Stock	160,000
Employee Stock Option (Right to Buy)	\$ 4.7						(2)	04/28/2015	Common Stock	300,000
Employee Stock Option (Right to Buy)	\$ 1.88						(3)	06/05/2016	Common Stock	300,000

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
CIALLELLA SUSAN STRANAHAN 107 STONEPINE DRIVE KENNETT SQUARE, PA 19348			Former Director and Officer	

## Signatures

/s/ Susan Stranahan  
Ciallella 06/12/2007

\_\_Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The reported transactions involved amendments and modifications to certain outstanding option grants. The Company and Ms. Ciallella entered into a Settlement Agreement and Release, dated as of June 8, 2007 (the "Settlement Agreement"). Under the original terms of this
- (1) option grant, the option was to vest in 12 equal installments on a quarterly basis over a three year period commencing July 13, 2006. Pursuant to the terms of the Settlement Agreement, the amount is fully vested and will expire 10 years from the date of its original issue date.

## Edgar Filing: ISOLAGEN INC - Form 4

- (2) This option is fully vested and will expire 10 years from the date of its original issue date. The terms of this option was not modified by the Settlement Agreement.

Pursuant to the terms of the Settlement Agreement, the number of shares of the Company's common stock subject to the June 2006

- (3) Non-Qualified Stock Option grant was reduced from 400,000 to 300,000 shares, This option is fully vested and will expire 10 years from the date of its original issue date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.